[The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
The aim of our study was to compare the striatal dopamine D2-receptor density as measured by 123I-IBZM-SPECT with the results of the apomorphine-test. 30 patients were studied; 21 with idiopathic Parkinson's disease (IPD), 9 with Parkinson plus syndromes (PPS). Patients with IPD showed a significantly higher striatal IBZM binding as compared to patients with PPS (p = 0.006). A good correlation between IBZM binding and outcome of the apomorphine-test was found (p = 0.006). Low striatal IBZM binding indicates reduced dopamine D2-receptor density. This compromises successful dopaminergic medical therapy and is indicative of non-IPD disease. 123I-IBZM-SPECT could be diagnostic aid in the work-up of patients with extrapyramidal movement disorders. The response to dopaminergic drug treatment might be precluded by IBZM-SPECT in patients with Parkinsonian syndromes.
Hierholzer
J
J
Strahlenklinik und Poliklinik, Klinikum Rudolf Virchow, Freie Universität Berlin.
Cordes
M
M
Schelosky
L
L
Sander
B
B
Böck
J C
JC
David
I
I
Horowski
R
R
Poewe
W
W
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001058:Apomorphine; D001480:Basal Ganglia Diseases / Q000000981:diagnostic imaging*; D001549:Benzamides; D003287:Contrast Media; D003937:Diagnosis, Differential; D065127:Dopamine D2 Receptor Antagonists; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging*; D011759:Pyrrolidines; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon
D001549:Benzamides; D003287:Contrast Media; D065127:Dopamine D2 Receptor Antagonists; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D001058:Apomorphine
Differentialdiagnose der Parkinson-Erkrankungen--123I-IBZM-SPECT vs. Apomorphin-Test.